Key result
Apixaban provides significant clinical benefits for stroke prevention in elderly patients with non-valvular atrial fibrillation, demonstrating superior efficacy and a lower risk of major bleeding compared to warfarin and aspirin.
Why the study?
To review the opportunity and clinical evidence for using apixaban to prevent stroke and/or systemic embolism in elderly patients with non-valvular atrial fibrillation.
Does apixaban reduce the risk of stroke and systemic embolism in elderly patients with non-valvular atrial fibrillation compared to warfarin or acetylsalicylic acid?
Does apixaban reduce the risk of stroke and systemic embolism in elderly patients with non-valvular atrial fibrillation compared to warfarin or acetylsalicylic acid?
Apixaban is a highly effective and safe oral anticoagulant for stroke prevention in elderly and very elderly patients with non-valvular atrial fibrillation, offering superior clinical benefit over warfarin and aspirin.
Answers are grounded in this paper and cite their sources.
Apixaban supports stroke prevention in elderly AF patients; confirms net benefit in ARISTOTLE and AVERROES subgroups aged ≥75–85 years.
In review article, we discuss the opportunity of use of one of the direct oral anticoagulants – apixaban – for prevention of stroke and/or systemic embolism in elderly patients with non-valvular a trial fibrillation. We consider results of randomized clinical trials of apixaban – ARISTOTLE and AVERROES, including the subgroups analysis in patients in the age of ≥75 years and ≥80 years – in ARISTOTLE, ≥75 years and ≥85 years – in AVERROES. These studies have shown that elderly patients had more benefit from apixaban administration than warfarin (in ARISTOTLE) or acetylsalicylic acid (in AVERROES). The results of two retrospective observational studies confirming the favorable profile of apixaban effectiveness and safety in elderly patients with a trial fibrillation in real clinical practice, and the main provisions of the consensus document FORTA, the purpose of which is to individualize treatment of elderly patients based on clinical characteristics of the patient, are also considered.
No takes yet. Share an insight, caveat, or question.
Vorobyeva et al. (2020) conducted a review in Non-valvular atrial fibrillation. Apixaban vs. Warfarin or Acetylsalicylic acid was evaluated. Apixaban provides significant clinical benefits for stroke prevention in elderly patients with non-valvular atrial fibrillation, demonstrating superior efficacy and a lower risk of major bleeding compared to warfarin and aspirin.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: